Prolonged exposure to 5- ARIs does not impair detection of prostate cancer on MRI: Study

A group of researchers from Cleveland, Ohio, U.S.A. conducted a study to evaluate the influence of 5-ARIs on the performance of MRI for detection of Gleason grade group (GG) ≥2 prostate cancer, and on apparent diffusion coefficient (ADC) maps.

The researchers conducted this single-center, retrospective study wherein they included men who had MRI for initial detection or active surveillance of prostate cancer. The study group included a total of 59 men who used for 5-Alpha Reductase Inhibitors (5-ARIs) for ≥12 months, and the control group included a total of 59 men who were matched for both MRI indication and biopsy results. DeLong's test was used to compare the area under the receiver operating curve (AUC) for the detection of GG ≥2 cancer between the groups. Wilcoxon rank-sum test was used for comparison of lesions ADC metrics between the groups.

The results of the study are as follows:

• MRI accuracy in the study group (AUC=0.778) was not significantly different compared to the control group (AUC=0.821).
• In the control group, all ADC metrics were lower in lesions with GG ≥2 cancer on biopsy than in those with GG 1 cancer or negative results.
• In the study group, this difference was significant only when the mean ADC of the lesions was normalized by the ADC of urine.

The authors concluded that long-term exposure to 5-Alpha Reductase Inhibitors (5-ARIs) does not seem to impair the detection of significant cancer on MRI but may affect the ability of apparent diffusion coefficient (ADC) metrics to discriminate between lesions that harbor significant cancer and those that harbor insignificant cancer or benign tissue.

Reference:

A study titled. "Influence of 5-Alpha Reductase Inhibitors on Prostate Cancer Detection With MRI: A Matched Cohort Study" by Purysko A et. al published in The Journal of Urology.

DOI: https://doi.org/10.1097/JU.0000000000001932